

## LETTER TO THE EDITOR

## Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient

*Blood Cancer Journal* (2014) 4, e176; doi:10.1038/bcj.2013.72; published online 17 January 2014

T-cell acute lymphoblastic leukemia (T-ALL) originates from multiple gene alterations occurring in normal precursor T cells, and represents 20% of adult ALL cases. Several recurrent cytogenetic abnormalities, cryptic cytogenetic aberrations, micro-deletions and other genomic changes were described using fluorescence *in situ* hybridization (FISH) arrays and gene expression and mutation analysis. Among the alterations affecting cell growth and differentiation mechanisms,<sup>1,2</sup> a key pathogenetic role was demonstrated for *NOTCH1*-activating mutation, detectable in about 60% of the cases, with or without associated *FBXW7* gene inactivation. Other frequent findings are *CDKN2A/2B* deletions and T-cell receptor (*TCRB*, *TCRA-TCRD*) gene translocations involving transcription factor (*TAL1*, *TAL2*, *LYL1*, *LMO1*, *LMO2*, *LMO3*, *TLX1*, *TLX3*, *NKX2.1*, *NKX2.2*, *HOXA*, *MYC*), tumor suppressor (*WT1*, *LEF1*, *ETV6*, *RUNX1*, *GATA3*) and signal transduction (*PTEN*, *ABL1*, *NRAS*, *JAK1*, *JAK3*) genes. Various combined, these abnormalities concur to identify distinct molecular and prognostic subsets that could be targeted by new biology response modifiers to enhance the probability of cure.


Translocation t(8;14)(q24;q11), first reported in pediatric patients and detectable in about 1% of T-ALL cases, is the hallmark of an extremely aggressive syndrome characterized by hyperleukocytosis, lymphoma-like presentation, rapid neurological progression and poor response to chemotherapy.<sup>3</sup> In t(8;14)(q24;q11), the *MYC* proto-oncogene, which is also a target of *NOTCH1* activation and maps at 8q24, is activated and fused to *TCRA/D* genes, exerting transcriptional repression of cell cycle inhibitors p27 and p21. Because of its rarity, t(8;14)+ T-ALL is almost unknown (or under-recognized) in adults. In the MRC-ECOG study recruiting 782 successfully karyotyped patients, no t(8;14)+ T-ALL was recognized, although there were 102 patients with unspecified abnormal karyotypes,<sup>4</sup> and no t(8;14)+ T-ALL was identified in two large series from the same group ( $n = 356$ ) and GIMEMA ( $n = 90$ ).<sup>5,6</sup>

We identified an adult patient with t(8;14)+ T-ALL in whom a thorough clinico-laboratoristic investigation was performed, including the combined interphase (CI) FISH study of several genes potentially involved in T-ALL pathogenesis and the molecular evaluation of minimal residual disease (MRD). This 44-year-old male suffering from backache and malaise for 3 days before referral presented with a white blood cell (WBC) count of  $251 \times 10^9/l$  (100% lymphoblasts), hemoglobin 16.4 g/dl, platelets  $159 \times 10^9/l$ , modest diffuse lymphadenopathies, and enlarged spleen and liver palpable 5 and 3 cm below the costal margin, respectively. The chest film showed a mediastinal mass (34% of the transverse chest diameter), while routine biochemistry

indicated liver involvement (aspartate transaminase 216 U/l, alanine transaminase 188 U/l, alkaline phosphatase 493 U/l, gamma glutamyl-transferase 303 U/l, bilirubin 0.7 mg/dl), preserved renal function (urea 36 mg/dl, creatinine 1.28 mg/dl, creatinine clearance 99 ml/min, sodium 144 mmol/l, potassium 3.8 mmol/l, chloride 104 mmol/l, calcium 10.4 mmol/l), and high risk for tumor lysis syndrome (lactate dehydrogenase 5079 U/l, uric acid 9.1 mg/dl).

Flow cytometry analysis confirmed T-ALL with late cortical immunophenotype: cyCD3 94%, CD7 97%, CD2 92%, CD5 95%, CD4 70%, CD8 94%, CD1a 82%, sCD3 92%; nuclear TdT was poorly expressed (11%), CD56 was 3% and myeloid/stem cell antigens were CD33 7%, CD117 70% and CD34 70% (CD13 not assessed). The cytogenetic analysis, performed according to Quinacrine-banding of 24 and 48 h unstimulated cell cultures, showed a 46 XY, t(8;14)(q24;q11)[13]/46 XY[3] karyotype (Figure 1a). The concurrent involvement of *MYC* proto-oncogene and *TCRA/D* genes was confirmed by FISH on metaphases exposed to LSI *MYC/IGH/CEP8* tricolor dual fusion and LSI *MYC* and *TCRA/D* break apart Vysis probes: t(8;14)(D8Z1+, 5' *MYC* +, 3' *TCRA/D* +; 5' *TCRA/D* +, 3' *MYC* +)[10]. Thirty-one genes, mapping as indicated in brackets and known to be implicated in T-ALL pathogenesis, were studied by CI FISH as previously reported:<sup>7</sup> *TCRB* (7q34), *TCRAD* (14q11), *TAL1* (1p32), *FBXW7* (4q31), *LEF1* (4q25), *TLX3* (5q35), *GRIK2* (6q16), *CASP8AP2* (6q15), *C-MYC* (6q23), *IKAROS* (7p11), *CDKN2A* (9p21), *JAK2* (9p24), *ABL1* (9q34), *NUP214* (9q34), *NOTCH1* (9q34), *PTEN* (10q23), *WT1* (11p13), *LMO2* (11p13), *NUP98* (11p15), *CALM* (11q14), *MLL* (11q23), *ETV6* (12p13), *RB1* (13q14), *NF1* (17q12), *PTPN2* (18p12), *AF10* (10p13), *C-MYC* (8q24), *BCL11B* (14q32), *AML1* (21q22), *ERG* (21q22) and *PHF6* (Xp11). The analysis confirmed t(8;14)(q24;q11) involving *TCRA/D* and *MYC* genes in 98% and 82% of the cells studied, respectively. *NOTCH1* and *FBXW7* genes were not mutated (this being also excluded by denaturing high-performance liquid chromatography and sequencing), while additional aberrations consisted of *SIL-TAL1* gene deletion (82%), biallelic *CDKN2A/B* gene deletion (88%), 10p13/*AF10* gene gain (86%) and del(10)(q23)/*PTEN* deletion in a leukemic subclone (12%) (Figure 1b). Two molecular case-specific probes were generated to perform serial MRD evaluations (probe 1: *TAL* deletion type 1, sensitivity  $10^{-5}$ ; probe 2: Jbeta 2.3, sensitivity  $10^{-5}$ ).

Although leukapheresis and rasburicase were immediately applied to prevent an acute tumor lysis syndrome, the WBC count increased to  $400 \times 10^9/l$  after 14 h, for an extrapolated doubling time of circulating blast cells of 23 h. Two more leukaphereses were performed and prephase therapy started. Treatment response is detailed in Figure 2. The induction block of the Northern Italy Leukemia Group (NILG) ALL protocol 10/07 (ClinicalTrials.gov NCT-00795756)<sup>8</sup> led to a prompt hematological response (neutrophils and platelets  $>1$  and  $>100 \times 10^9/l$ , respectively) 20 days after diagnosis, the patient being discharged home 22 days after admission. On day 23 a complete hematologic, cytogenetic and molecular remission (CR)



**Figure 1.** (a)  $t(8;14)(q24;q11)$  in a patient with T-ALL. (b) CI FISH results (the full list of gene-specific CI-FISH probes is available upon request to the authors): 1. *TCRA/D* (RP11-242H9 + RP11-447G18, 14q11) break-apart FISH assay showing a split signal. 2. *C-MYC* (RP11-367L7 + RP11-26E5, 8q24) break-apart-test abnormal pattern consisting of one fusion, one orange and one green signal. 3. Interphase nucleus showing (arrow) a biallelic deletion of RP11-149I2 (*CDKN2A/B/9p21*), Spectrum Orange probe. In green, *ABL1* (RP11-57C19 + RP11-83J21, 9q34). 4. *SIL-TAL1* FISH probe detecting a *SIL/1p33* deletion (G248P80397F3, Spectrum Orange). 5. *AF10/10p13* Spectrum Orange specific probes (RP11-249M6 + RP11-418C1) showing the presence of three signals. 6. Nuclei hybridized with RP11-380G5/*PTEN*, Spectrum Orange, and RP5-926B9 + RP5-1002G3/*NF1*, Spectrum Green, proving (arrow) a *PTEN/10q23* monoallelic deletion.

was confirmed, with MRD signals  $< 10^{-4}$ . Additional MRD tests were performed after cycle 3 and after allogeneic SCT at day 30, 100 and 180. A complete MRD clearing was documented after cycle 3 and maintained in all subsequent evaluations. Because with modern regimens T-ALL relapse is rarely observed after 18–24 months<sup>5,9</sup> and the patient is disease-free at 29 months from CR and off-therapy 26 months after SCT, the probability of cure appears very high.


T-ALL carrying  $t(8;14)$  is very rare in adults and confers a dismal outlook. In the August 2013 update of the Mitelman registry,<sup>10</sup> 5 adult cases are reported in patients older than 15 years (range 17–35 years), compared with 31 childhood cases. The WBC count of the adult patients ranged between 46.6–320 and only one survived (67 months). Additional chromosomal alterations were detected in four:  $del(6)(q13q21), del(9)(p22); add(9)(p21), del(10)(q?), -14, +21; +i(7)(q10), -4, -Y, del(6)(q15q23);$  and  $t(1;4)(p32;p12)$ . The case with  $t(8;14)$  as sole abnormality, like ours, had the highest WBC count ( $320 \times 10^9/l$ ). An additional molecular study was performed in one case, excluding alterations of *SIL-TAL1*, *HOX11L2*, *HOX11*, *CALM-AF3*, *MLL* and *CALM-AF5* genes.

Our report suggests that cure is possible in adult patients with this hyperkinetic ALL subset, possibly the fastest growing ever reported. The disease was of apparent thymic origin, as indicated by the enlarged mediastinum, the late cortical CD1a + sCD3 + phenotype, and the preserved hemoglobin and platelet count, indicating a late marrow involvement. Its enormous proliferative capability was the most striking feature, to put in relation with the underlying gene abnormalities. The main lesion was  $t(8;14)(q24;q11)$ , which differs from  $t(8;14)(q24;q32)$  of Burkitt leukemia/lymphoma (BL) for the different breakpoint in chromosome 14, fusing *MYC* to *TCRA/D* genes instead of immunoglobulin genes. BL is the most rapidly proliferating of all B-cell neoplasms, and is also TdT-negative, like a small fraction of T-ALLs, which is another interesting analogy with the current T-ALL case.<sup>11</sup> Thus, all high WBC count and/or TdT-negative T-ALLs should be accurately screened for  $t(8;14)(q24;q11)$  and *MYC* rearrangements, in order to identify this elusive and highly

malignant ALL syndrome. CI FISH appears particularly suitable as a rapid and sensitive diagnostic method, simultaneously providing useful information on associated genetic abnormalities, especially when no other cytogenetic alteration is detectable. In this case, the absence of *NOTCH1* and *FXWB7* gene mutations excludes a pathogenetic role of the former and portrays a worse clinical outcome. This case would belong to the recently recognized *NOTCH1*-independent/*MYC*-mediated T-ALL subsets, in which a concurrent *PTEN* downregulation, here present in a leukemic subclone, or other mutations, can act as a major pathway of *MYC* activation.<sup>12,13</sup> The concurrent *CDKN2A/2B* biallelic gene deletion is associated with the loss of other tumor suppressor genes (*P16INK4A*, *P14ARF*), to complete the picture of a hyperproliferative acute T-cell malignancy, with a central pathogenetic role for *MYC* activation.

In spite of the explosive growth rate, treatment was successful by employing a new intensive regimen preliminarily associated with an excellent outcome of adult T-ALL (74% overall and disease-free survival at 2 years in 24 patients) and high MRD early negativity rate (78% of high-risk patients with MRD  $< 10^{-4}$  at week 10, that is, after course 3).<sup>8</sup> The treatment schedule featured an extensive use of cyclophosphamide, dexamethasone, and antimetabolites such as cytarabine—both standard and high-dose, 6-mercaptopurine and methotrexate 5g/m<sup>2</sup> in keeping with pharmacokinetic studies in T-ALL,<sup>14</sup> together with the shortest possible intercycle intervals to counteract the high rebound potential of the leukemic clone. Similar treatment concepts allowed to improve significantly the outcome of BL, the B-cell counterpart of  $t(8;14)/MYC + ALL$ .<sup>15</sup>

In conclusion,  $t(8;14)(q24;q11) + T-ALL$  is a rare, highly malignant syndrome sometimes observed in adult patients. The case herein described would exemplify the outer limits of the clinical aggressiveness of the disease. Even so, prompt recognition and careful start of management with modern T-ALL-specific therapy can warrant good therapeutic results, including an early complete molecular response. CI FISH analysis was essential to



**Figure 2.** Schematic representation of clinical course and therapeutic response. Following an early rise in total WBC count soon after diagnosis, a rapid, complete hematological, cytogenetic (46,XY[20]), immunophenotypic ( $<1$  CD1a/CD4/CD8/CD7/CD45<sup>+</sup> cell  $\times 10^3/\mu l$ ) and molecular MRD ( $1.9 \times 10^{-5}$  with probe;  $3.5 \times 10^{-5}$  with probe 2) remission was achieved after pre-phase and chemotherapy block 1. Three postremission consolidation blocks were administered in tight sequence, recycling on days 24 (block 2: cyclophosphamide, idarubicin, dexamethasone, cytarabine, 6-mercaptopurine, triple intrathecal therapy), 46 (block 3: high-dose methotrexate 5 g/m<sup>2</sup> and cytarabine 2 g/m<sup>2</sup>) and 65 (block 4: like cycle 2). Because of being classified as very high risk, the patient was eligible for allogeneic stem cell transplantation (SCT) from a compatible sibling donor. On day 99 from diagnosis and following conditioning with total body irradiation, cyclophosphamide and anti-thymocyte globulin, the patient received a peripheral blood unmanipulated stem cell graft from his fully HLA/DR-matched sister (nucleated cells  $10.7 \times 10^8/kg$ , CD3<sup>+</sup> T cells  $209.7 \times 10^6/kg$ , CD34<sup>+</sup> cells  $4.3 \times 10^6/kg$ ). Apart from mild chronic graft-vs-host disease, no major or life-threatening complication occurred in the post-transplantation period, and he remains well and alive in CR1 more than 2 years from diagnosis.

highlight distinct routes of molecular pathogenesis centered around *MYC* gene activation, and as such may contribute to identify new meaningful *NOTCH1*-independent targets within these dysregulated metabolic pathways.

#### CONFLICT OF INTEREST

The authors declare no conflict of interest.

M Parolini<sup>1</sup>, C Mecucci<sup>2</sup>, C Matteucci<sup>2</sup>, U Giussani<sup>3</sup>, T Intermesoli<sup>1</sup>, M Tosi<sup>1</sup>, A Rambaldi<sup>1</sup> and R Bassan<sup>1,4</sup>

<sup>1</sup>U.S.C. Ematologia, Ospedale Papa Giovanni XXIII, Bergamo, Italy;

<sup>2</sup>Ematologia e Immunologia Clinica, Dipartimento di Medicina Clinica e Sperimentale, Università di Perugia, Perugia, Italy and

<sup>3</sup>Laboratorio di Genetica Medica, Ospedale Papa Giovanni XXIII, Bergamo, Italy

E-mail: renato.bassan@ulss12.ve.it

<sup>4</sup>Current address: U.O.C. Ematologia, Ospedale dell'Angelo e Ospedale SS. Giovanni e Paolo, Venezia, Italy

#### REFERENCES

- Kraszewska MD, Dawidowska M, Szczepański T, Witt M. T-cell acute lymphoblastic leukaemia: recent molecular biology findings. *Br J Haematol* 2012; **156**: 303–315.
- Van Vlierberghe P, Ferrando A. The molecular basis of T cell acute lymphoblastic leukemia. *J Clin Invest* 2012; **122**: 3398–3406.
- Lange BJ, Raimondi SC, Heerema N, Nowell PC, Minowada J, Steinherz PE *et al*. Pediatric leukemia/lymphoma with t(8;14)(q24;q11). *Leukemia* 1992; **6**: 613–618.
- Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M *et al*. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. *Blood* 2007; **109**: 3189–3197.
- Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G *et al*. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). *Blood* 2009; **114**: 5136–5145.
- Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A *et al*. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. *Blood* 2006; **107**: 473–479.

- 7 Gorello P, La Starza R, Varasano E, Chiaretti S, Elia L, Pierini V *et al.* Combined interphase fluorescence in situ hybridization elucidates the genetic heterogeneity of T-cell acute lymphoblastic leukemia in adults. *Haematologica* 2010; **95**: 79–86.
- 8 Bassan R, Masciulli A, Spinelli O, Interimesoli T, Oldani E, Rossi G *et al.* New first line chemotherapy program with lineage targeted methotrexate infusions is feasible and improves the early minimal residual disease response and survival in acute T-lymphoblastic leukemia. *Haematologica* 2011; **96**(Suppl 2): 238 (abstract 0557).
- 9 Ben Abdelali R, Asnafi V, Leguay T, Boissel N, Buzyn A, Chevallier P *et al.* Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study. *Blood* 2011; **118**: 5099–5107.
- 10 Mitelman F, Johansson B, Mertens F (eds). *Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer*, 2013, <http://cgap.nci.nih.gov/Chromosomes/Mitelman>.
- 11 Zhou Y, Fan X, Routbort M, Cameron Yin C, Singh R, Bueso-Ramos C *et al.* Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. *Mod Pathol* 2013; **26**: 1338–1345.
- 12 Bonnet M, Loosveld M, Montpellier B, Navarro JM, Quilichini B, Picard C *et al.* Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. *Blood* 2011; **117**: 6650–6659.
- 13 Rakowski LA, Garagiola DD, Li CM, Decker M, Caruso S, Jones M *et al.* Convergence of the ZMIZ1 and NOTCH1 pathways at C-MYC in acute T lymphoblastic leukemias. *Cancer Res* 2013; **73**: 930–941.
- 14 Masson E, Relling MV, Synold TW, Liu Q, Schuetz JD, Sandlund JT *et al.* Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. *J Clin Invest* 1996; **97**: 73–80.
- 15 Interimesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM *et al.* High cure rates in Burkitt lymphoma and leukemia: NILG study of the German short intensive rituximab-chemotherapy program. *Haematologica* 2013; **98**: 1718–1725.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/3.0/>